Oncolytics Biotech Inc. (TSE:ONC - Free Report) - HC Wainwright decreased their FY2028 earnings per share estimates for Oncolytics Biotech in a report released on Monday, March 10th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of $0.57 per share for the year, down from their previous estimate of $0.60. The consensus estimate for Oncolytics Biotech's current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech's FY2029 earnings at $1.06 EPS.
Separately, Raymond James upgraded Oncolytics Biotech to a "moderate buy" rating in a research report on Thursday, November 14th.
Check Out Our Latest Stock Analysis on ONC
Oncolytics Biotech Stock Performance
TSE:ONC remained flat at C$0.91 during trading hours on Wednesday. The company's stock had a trading volume of 12,237 shares, compared to its average volume of 125,195. Oncolytics Biotech has a 12 month low of C$0.86 and a 12 month high of C$2.08. The company has a current ratio of 2.99, a quick ratio of 8.86 and a debt-to-equity ratio of 11.75. The business's 50-day moving average price is C$1.10 and its 200-day moving average price is C$1.30. The firm has a market capitalization of C$70.14 million, a P/E ratio of -2.54 and a beta of 1.35.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
